Sign in to view content

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S

Allen Chiang, MD, FASRS

Video
Published 2019

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Do Anti-VEGF Injections Affect the Development of Neovascular AMD in Fellow Eyes? A Meta-analysis of Clinical Trials
Robert L. Avery, MD
Annual Meeting Talks
2018
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more